Tech Company Financing Transactions
Annovis Bio Funding Round
On 4/10/2026, Annovis Bio secured $10 million in investment from private investors.
Transaction Overview
Company Name
Announced On
4/10/2026
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Undisclosed
Investors
private investors (Michael Hoffman)
Proceeds Purpose
Proceeds from this offering will primarily support the advancement of buntanetap through the pivotal Phase 3 AD trial (NCT06709014), which is approaching full enrollment with 75% of participants already enrolled.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Drive 225
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Driven by a clear vision, we are working toward a future where neurodegenerative diseases are not a source of fear and despair, but challenges met with resilience and scientifically proven therapies. Our mission is to halt the death of nerve cells, presenting new hope for millions of patients and their families.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maria Maccecchini
Vice President
Michael Christie
VP - Marketing
Alexander Morin
VP - Operations
Sarah Maccallum
VP - R & D
Cheng Fang
VP - Regulatory Affairs
Eve Damiano
Browse more venture capital transactions:
Prev: 4/10/2026: Plume Finder venture capital transaction
Next: 4/10/2026: Provally venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs